Elsevier partners with ESCMID to launch a new Open Access journal in microbiology and infectious disease: CMI Communications

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open-access journal CMI Communications in partnership with ESCMID(opens in new tab/window), Europe’s leading society in clinical microbiology and infectious diseases.

Complementing and integrating with ESCMID’s prestigious official journal Clinical Microbiology and Infection(opens in new tab/window) (CMI, Impact Factor 14.2), CMI Communications(opens in new tab/window) will publish manuscripts focusing on translational and clinical aspects of microbiology, infectious diseases and control, immunology, epidemiology, and public health. A 50% discounted rate for publication is available for authors accepted for publication in CMI Communications in 2024 and 2025.

CMI Communications is led by Editor in Chief Angela Huttner, MD, a research investigator and infectious disease physician at Geneva University Hospitals, Switzerland. Dr Huttner commented, “We’re thrilled to be able to bring this project to life. The new journal will publish articles that are of practical use to infectious disease clinicians and clinical microbiologists—and thus to their patients. We particularly want to help early-career professionals broaden their skills, knowledge, and career opportunities. This means we must meet them where they are. First submissions will have almost no formatting requirements and turnaround times will be short. CMI Com will host a regular podcast, and its website will include interactive features allowing debate, knowledge transfer and other exchanges. The new journal should be thought of as a living platform — a sort of workbench, an endoplasmic reticulum where many little ribosomes can get together to build good things — and not as a bundle of papers arriving once a month in the mail.”

ESCMID President Prof. Annelies Zinkernagel added, “ESCMID is excited to be adding CMI Communications to its portfolio. The new journal will both complement CMI and be its own, unique forum for the exchange of further knowledge and ideas. While it will work closely with the ESCMID study groups and the Trainee Association of ESCMID to promote their work, it will be open to any and all researchers in clinical microbiology and infectious diseases wishing to communicate their ideas and share their results.”

On behalf of Elsevier, Executive Publisher Andrew Miller said, “We are proud to deepen our partnership with ESCMID on this inspiring new launch. CMI Communications fits very well with Elsevier’s mission to support researchers and clinicians by curating and enriching research with high-quality data and analytics, helping address challenges at every stage of the research and clinical-practice journey.”

About CMI Communications

CMI Communications(opens in new tab/window) is an interdisciplinary forum for knowledge exchange via the rapid publication of peer-reviewed original articles and reviews on basic, translational, and clinical aspects of microbiology, infectious diseases and control, immunology, epidemiology, and public health. Special attention is given to the application of experimental studies to ‘real-world’ clinical practice. The sister journal of Clinical Microbiology and Infection(opens in new tab/window), CMI Communications is fully open access.

About ESCMID

Since its founding in 1983, ESCMID(opens in new tab/window) has evolved to become Europe’s leading society in clinical microbiology and infectious diseases, with members from all European countries and all continents. For over 40 years, ESCMID has been an influential component in the professional lives of clinical microbiologists and infectious disease specialists. ESCMID has more than 11,000 individual members and around 56,000 affiliated members from around the world and the organizer of the largest congress in its field with over 16,000 participants. ESCMID is open and welcomes new colleagues from all nations.

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation(opens in new tab/window), we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.